This Article Full Text Full Text (PDF) All Versions of this Article: 34/1/171    most recent 01.STR.0000048216.90221.9Cv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Menniti, F. S. Articles by Welch, W. M. Search for Related Content PubMed PubMed Citation Articles by Menniti, F. S. Articles by Welch, W. M. Related Collections Primary prevention Acute Cerebral Infarction Neuroprotectors

(Stroke. 2003;34:171.)
© 2003 American Heart Association, Inc.

Original Contributions

CP-465,022, a Selective Noncompetitive AMPA Receptor Antagonist, Blocks AMPA Receptors but Is Not Neuroprotective In Vivo

Frank S. Menniti, PhD; Alistair M. Buchan, MD, FRCP; Bertrand L. Chenard, PhD; Donald J. Critchett, MS; Alan H. Ganong, PhD; Victor Guanowsky, MA; Patricia A. Seymour, PhD Willard M. Welch, PhD

From CNS Discovery, Pfizer Global Research and Development, Groton, Conn (F.S.M., D.J.C., A.H.G., V.G., P.A.S., W.M.W.); Department of Clinical Neuroscience, University of Calgary, Calgary, Alberta, Canada (A.M.B.); and Neurogen Corporation, Branford, Conn (B.L.C.).

Correspondence to Frank S. Menniti, Pfizer Global Research and Development, Eastern Point Rd, Groton, CT 06340. E-mail mennitifs{at}groton.pfizer.com

Background and Purpose— -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor inhibition has been hypothesized to provide neuroprotective efficacy after cerebral ischemia on the basis of the activity in experimental ischemia models of a variety of compounds with varying selectivity for AMPA over other glutamate receptor subtypes. CP-465,022 is a new, potent, and selective noncompetitive AMPA receptor antagonist. The present study investigated the ability of this compound to reduce neuronal loss after experimental cerebral ischemia to probe the neuroprotective potential of AMPA receptor inhibition.

Methods— To demonstrate that CP-465,022 gains access to the brain, the effects of systemic administration of CP-465,022 were investigated on AMPA receptor-mediated electrophysiological responses in hippocampus and on chemically induced seizures in rats. The compound was then investigated for neuroprotective efficacy in rat global and focal ischemia models at doses demonstrated to be maximally effective in the electrophysiology and seizure models.

Results— CP-465,022 potently and efficaciously inhibited AMPA receptor-mediated hippocampal synaptic transmission and the induction of seizures. However, at comparable doses, CP-465,022 failed to prevent CA1 neuron loss after brief global ischemia or to reduce infarct volume after temporary middle cerebral artery occlusion.

Conclusions— Given the high selectivity of CP-465,022 for AMPA over kainate and N-methyl-D-aspartate subtypes of glutamate receptors, the lack of neuroprotective efficacy of the compound calls into question the neuroprotective efficacy of AMPA receptor inhibition after ischemia.

Key Words: excitatory amino acid antagonists • receptors, AMPA • receptors, glutamate • stroke